0B68 Cristofanilli, Massimo - Thomas Jefferson University - Thomas Jefferson University
mxc156

Massimo Cristofanilli, MD

Contact Dr. Cristofanilli

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
  2. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy
  3. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination
  4. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer
  5. Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome
  6. Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival
  7. Circulating tumour cells: Telling the truth about metastasis
  8. Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC)
  9. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
  10. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations
  11. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
  12. Presence of anaplastic lymphoma kinase in inflammatory breast cancer
  13. The Third International Inflammatory Breast Cancer Conference
  14. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial
  15. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
  16. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
  17. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients
  18. Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets
  19. Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?
  20. Circulating tumor DNA to monitor metastatic breast cancer [5]
0